- GlobeNewswire•12 days ago
SYDNEY, Australia, April 18, 2017-- Prima BioMed Ltd today announced that approval has been granted for the third cohort of its Phase I clinical trial for IMP321 in combination with KEYTRUDA ® being conducted ...
- GlobeNewswire•19 days ago
SYDNEY, Australia, April 12, 2017-- Prima BioMed Ltd, is pleased to announce that it has received a A $492,144 cash rebate from the Australian Federal Government’ s R&D tax incentive program. The cash ...
- Marketwired•2 months ago
Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston
Prima BioMed Ltd announces that the second cohort comprising six patients has now been fully recruited for its TACTI-mel clinical trial being conducted in Australia. Patients with unresectable or metastatic ...
PBMD : Summary for Prima BioMed Ltd - American Dep - Yahoo Finance
Prima Biomed Ltd. (PBMD)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.54 x 1000|
|Ask||7.40 x 100|
|Day's Range||2.40 - 2.53|
|52 Week Range||0.51 - 3.26|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-8.33|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|